VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ByRaj Agrawal, MD

ByAlex Young

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Raj Agrawal, MD, discusses the initial results of a phase 2a study of a novel therapy for patients with diabetic macular edema.

Agrawal said RZ402 (Rezolute Bio), which is orally administered, demonstrated a significant change in central subfield thickness in the first-in-patient proof-of-concept study compared with placebo.

“I’m really excited about the fact that there is an oral medication that can potentially change the treatment paradigm for patients who currently have to keep coming back to the clinics over and over again to get injections,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Agrawal reports being vice president and head of ophthalmological clinical development at Rezolute Bio.

Clinical Trials at the Summit meeting

Read more

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

Related Content